WeiLiang Intervention Completes Tens of Millions RMB Pre-A Financing to Accelerate Commercialization of Active Energy-Based Endovascular Devices

VCBeat exclusively learned that, recently,Micro-Energy Medical Technology ( Hangzhou ) Co., Ltd. ( Hereinafter referred to as"Micro-Energy Medical"Announced the completion of a multi-million yuan Pre-A round of financing. This round of investment was led byTaiyu InvestmentLeading investment,Shenzhen Guochuang Qinzhi Angel FundAndHuagai CapitalFollow-on Investment,Hanyu CapitalContinuously serve as the exclusive financial advisor.

This round of financing also follows Micro-Energy Medical's acquisition in 2023.PwC CapitalTens of Millions in New Financing Within a Year After Angel Round. With the Support of New and Existing Shareholders, the Company Will Continue to Invest Heavily in the Development of Its Active Energy Vascular Intervention Product Portfolio and New Technologies; Accelerate Clinical Registration of Products; and Promote the Industrialization and Global Implementation of Its Products.

Micro-Energy Medical is an innovative medical technology company specializing in active energy intravascular interventional devices.The company was founded in 2021, with operations, production bases, and R&D offices in Hangzhou, Shenzhen, and Coburg, Germany.The core team is composed of senior experts from China and Germany.The Chinese team comes from Micro-Energy Medical, Mindray Medical, Edan Instruments, Peking Union Medical College, The Chinese University of Hong Kong, and others, with multidisciplinary research and development experience; the German team includes several top experts in the laser field. The founding team has extensive international strategic layout and business promotion capabilities.

Focusing on the field of active energy vascular intervention, Micro-Energy Medical has laid out its strategy for key indications with significant clinical needs.355nm Solid-State Pulsed Laser Vascular Ablation System, Differentiated Innovative Shock Wave Balloon System, Varicose Vein Laser Ablation System, and Laser Renal Artery Sympathetic Denervation System (RDN). Each product line is either globally leading or a domestic first in China.Among them, the varicose vein laser ablation system is expected to obtain domestic registration and be launched for sale by the end of 2024, while other product lines are also planned to enter the clinical trial stage successively this year.

In the future, Micro-Energy Medical will continue to focus on the active and passive energy endovascular intervention track, leveraging its rich technical reserves to continuously develop new products that address clinical pain points. At the same time, it will actively expand into overseas markets by utilizing its international sales background advantages. With the mission of "persisting in innovation, leading technology, and building a safe and effective micro-energy vascular intervention platform," and the vision of "becoming a global leader in vascular health protection," the company aims to create value for its customers.

For this round of financing,Micro-Energy MedicalExpressed: Thanks to Taiyu Investment, Guochuang Qinzhi, and Huagai Capital for their recognition of Micro-Energy Medical's team and products. Also, thanks to the existing shareholder, PuHua Capital, for their continued support and FA Hanyu Capital for their efficient work. With the help of capital, Micro-Energy Medical will accelerate the company’s research, development, and registration of active intravascular energy interventional products, striving to bring innovative products to market as soon as possible—serving patients and doctors, delivering returns to shareholders, and providing employees with an innovative platform for self-fulfillment.

Dr. Jirong Ji, Founding Partner of Taiyu InvestmentRepresentation: Taiyu Investment focuses primarily on medical device investments, with the active energy vascular intervention field being one of our key areas of interest. This field is highly innovative, has significant barriers to entry, and requires long-term accumulation of talent and technology. The Micro-Energy Medical team consists of senior experts from China and Germany, combining top-tier laser technology, medical device product development, and experience in operating and selling for startups. Their products effectively address clinical challenges related to vascular calcification and occlusion, placing them at the forefront of the industry.

Shenzhen Guochuang Qinzi FundThrough prolonged due diligence and communication, the highly efficient execution capability and excellent product layout of the Micro-Energy Medical team have left a deep impression. The core product, solid-state laser ablation system, demonstrates excellent performance in treating major diseases such as chronic total occlusion, moderate to severe vascular calcification, and intravascular restenosis, with the potential to overcome the "final frontier" of coronary intervention. As a shareholder of the company, Guochuang Qinzhi Fund will also actively leverage the resources of the National Innovation Center for High-Performance Medical Devices to empower Micro-Energy Medical and support the company’s development.

Huagai Southern Angel FundRepresentation: The market for coronary intervention in China continues to grow year by year. With the deepening of population aging, it is expected that the number of interventional surgeries will continue to increase in the future. Meanwhile, the number of peripheral arterial interventions both domestically and internationally is expected to grow rapidly with the launch of new devices. Additionally, as the increasing number of stent implantations leads to a rise in complex cases, we remain optimistic about device innovation companies in the field of pan-vascular intervention over the long term—especially companies like Micro-Energy Medical, whose cutting-edge innovation teams excel in both technology and global market strategy. Micro-Energy Medical, centered on its laser energy platform, has positioned itself in the fields of coronary and peripheral intervention, addressing significant clinical challenges such as severe vascular calcification and arterial embolism, which affect large patient populations. Compared to other energy platforms, the laser energy platform boasts extremely high technical barriers, a wide range of applications, and remains in a blue ocean phase within the medical field. The core team at Micro-Energy Medical has extensive experience in serial entrepreneurship and international market sales. By developing products at different levels, pursuing dual regulatory approvals overseas, and formulating mid-to-short-term sales strategies, the company is actively expanding into international markets. We look forward to Micro-Energy Medical’s differentiated development path bringing new perspectives to the industry.

Yang Li, Partner of PuHua CapitalMicro-Energy Medical has a very comprehensive team specializing in the R&D, production, and registration of high-end medical devices. From the R&D perspective, they master upstream foundational technologies and have developed core products based on multiple energy treatment platforms that are suitable for doctors to use and effectively address clinical needs. They resolve core issues at the source: 1. The issue of self-developed core components; 2. The problem of existing treatment methods requiring patients to be at specific stages or conditions; 3. A significant number of patients still lack effective treatment options. VCBeat is very honored to have collaborated with such an outstanding team from the angel stage, committing to fill the gap in the active medical device treatment market.

Jin Binchao, Founding Partner of Hanyu CapitalMicro-Energy Medical: Focused on the underdeveloped track of active energy intervention with significant clinical value and market potential, offering a wide range of applications but with high barriers that require close collaboration across multiple disciplines. The team, having worked together for a long time, demonstrates exceptional problem-solving capabilities and execution strength, achieving rapid product development progress. It is also one of the few founding teams with extensive experience in R&D management and overseas sales promotion.

Taiyu Investment focuses on equity investments in the early and growth-stage healthcare sector. The management team has a deep industry background, extensive industry resources, and rich investment experience. To date, it has completed investments totaling 20 billion yuan across more than a hundred projects. The investment portfolio covers medical devices, biopharmaceuticals, CRO, and health foods. By empowering its portfolio companies, Taiyu Investment creates value for the development of the healthcare industry in China and even globally, contributing to public health.

The Angel Investment Fund for the Great Health Industry of Guochuang Qinzhi, initiated jointly by Guochuang Zhiyuan, the capital operation platform under the National Innovation Center for High-Performance Medical Devices (hereinafter referred to as "Guochuang Center"), and Qinzhi Capital, has a fund size of 300 million yuan. Relying on the advanced technology advantages in the high-end medical device field and the national industrial platform advantages of the Guochuang Center, the fund leverages Qinzhi Capital's industrial investment capabilities and fund management abilities, focusing on investment in the healthcare sector. It aims to integrate the innovation chain, industry chain, and capital chain, incubate the next generation of "unicorns" in the healthcare field, and enhance the global competitiveness of China’s healthcare industry.

Huagai Capital, founded in 2012, is a private equity investment firm jointly established by a group of professionals from well-known investment institutions both within and outside China. With the vision of "becoming the most trusted capital partner for entrepreneurs and investors," the company focuses on private equity investments in the two major fields of healthcare and technology, and is committed to promoting the growth of small and medium-sized enterprises into industry leaders. Currently, the company manages assets of approximately 20 billion RMB.

Puhua Capital was founded in 2004, with its headquarters in Hangzhou and offices in Beijing, Shanghai, Shenzhen, and London, UK. It focuses on investments in four major fields: cutting-edge technology, new energy and materials, healthcare, and consumer culture. With a deep understanding of the industry and extensive experience in the capital markets, Puhua has established a "capital + industry" dual-driven strategy, committing to invest early, invest in innovation, invest in specialization, and invest for growth, acting as a nurturer and accelerator for entrepreneurship and innovation. Currently managing over 25 billion RMB, it has continuously supported the development of nearly 500 startups, of which more than 150 have exited through IPOs or other means.